With 180 patients and one-sided alpha of 0.10 , there would be 90 % power to detect an absolute 20 % difference in undetectable prostate-specific antigen ( PSA ; 0.2 ng/mL ) rate at 28 weeks ( relative risk , 1.44 ) ; this end point was previously strongly correlated with survival .